Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Silence Therapeutics plc is a biotechnology company focused on the discovery and development of RNA interference (RNAi)–based therapeutics. The company operates within the biopharmaceutical and genetic medicines industries, with a strategic emphasis on diseases where gene silencing can provide durable therapeutic benefit. Its core expertise lies in the design and delivery of short interfering RNA (siRNA) molecules intended to selectively inhibit disease-causing genes.
The company’s primary value drivers are its wholly owned clinical and preclinical RNAi programs and its proprietary delivery platform. Silence Therapeutics is positioned as a platform-based RNAi company with a focus on liver-targeted and extrahepatic gene silencing, differentiating itself through its internal chemistry and delivery technologies. The company was founded in 1994 and has evolved from early antisense research into a specialized RNAi therapeutics developer, rebranding as Silence Therapeutics to reflect its strategic focus on gene silencing technologies.
Business Operations
Silence Therapeutics operates through a single integrated business model centered on RNAi drug discovery and development. Its operations encompass target identification, siRNA design, preclinical development, and clinical-stage drug development, with revenue historically derived from research collaborations, licensing agreements, and milestone payments rather than product sales. The company’s pipeline includes wholly owned candidates targeting rare hematologic and cardiovascular-related disorders.
The company controls its proprietary mRNAi GOLD™ delivery platform, which is designed to enable efficient and durable gene silencing in specific tissues. Silence Therapeutics conducts its research and development primarily through internal teams and contract research organizations, without large-scale commercial manufacturing. It has previously entered into strategic collaborations with large pharmaceutical companies, though its current strategy emphasizes advancing internally owned assets through clinical development.
Strategic Position & Investments
Silence Therapeutics’ strategic direction prioritizes advancing its lead clinical programs while expanding its RNAi platform to address additional genetic and cardiometabolic diseases. Growth initiatives focus on progressing late preclinical and early clinical assets, particularly programs targeting genetically defined patient populations where regulatory pathways may be more streamlined.
The company has made sustained investments in expanding the applicability of its RNAi delivery technologies beyond the liver, which is a competitive differentiator in the RNAi field. While Silence Therapeutics does not operate as a holding company with a broad portfolio of subsidiaries, it maintains full ownership of its core intellectual property and development programs. Public disclosures do not indicate material recent acquisitions; instead, the company’s investment strategy centers on internal R&D and selective external collaborations.
Geographic Footprint
Silence Therapeutics is headquartered in London, United Kingdom, with significant research operations in Berlin, Germany, reflecting its European roots and scientific talent base. These locations support the company’s discovery, preclinical research, and clinical development activities.
Although operationally concentrated in Europe, the company maintains a global outlook, with clinical trials, regulatory interactions, and investor engagement extending into North America. Its ordinary shares are listed on the London Stock Exchange, and its American Depositary Shares trade on NASDAQ, supporting international capital access and visibility.
Leadership & Governance
Silence Therapeutics is led by an experienced executive team with backgrounds in biotechnology, pharmaceuticals, and RNA-based drug development. The leadership emphasizes scientific rigor, disciplined capital allocation, and the advancement of proprietary platform technologies into clinically validated medicines.
Key executives include:
- Ali Jelveh – President and Chief Executive Officer
- Philippe Gielen – Chief Financial Officer
- Dr. Nadja Kanter – Chief Development Officer
- Dr. Andy Oakley – Chief Scientific Officer
The company is governed by a board of directors with experience across life sciences, finance, and public company governance, supporting its strategic focus on long-term value creation through innovation in RNAi therapeutics.